Comment
Author: Admin | 2025-04-28
50 Gy group, representing an absolute difference of -0·7% (95% CI -1·7% to 0·9%)-ie, the absolute difference in local-regional relapse could be up to 1·7% better and at most 1% worse after 40 Gy than after 50 Gy. Photographic and patient self-assessments indicated lower rates of late adverse effects after 40 Gy than after 50 Gy. Interpretation: A radiation schedule delivering 40 Gy in 15 fractions seems to offer rates of local-regional tumour relapse and late adverse effects at least as favourable as the standard schedule of 50 Gy in 25 fractions.## [2] EBCTCG (Early Breast Cancer Trialists' Collaborative Group). Effect of radiotherapy after mastectomy and axillary surgery on 10-year recurrence and 20-year breast cancer mortality: meta-analysis of individual patient data for 8135 women in 22 randomised trials. Lancet 2014; 383: 2127–35—During revision of the appendix of this Article after peer review, some analyses of local recurrence were omitted. These have now been restored in the updated appendix. All analyses (and page numbers) in the previous version of the appendix remain unchanged, as do the medical findings of the paper. The correction has been made to the appendix as of Nov 21, 2014. ## [3] The proceedings contain 2121 papers. The topics discussed include: radiation treatment parameters and late gastrointestinal toxicity in cervical cancer patients treated with image guided high-dose-rate brachytherapy; the effect of pelvic radiation therapy on vaginal brachytherapy cylinder size; role of radiation therapy in platinum-resistant recurrent ovarian cancer diagnosed by FDGPET/contrast-enhanced CT; inferior outcomes following definitive radiation therapy or concurrent chemoradiation therapy for adenocarcinoma than squamous cell carcinoma of uterine cervix: a matched case control study; first safety analysis after 80 treated patients with early breast cancer within the targit-e trial; accelerated partial-breast irradiation (APBI) provides equivalent 5 year and 10 year outcomes regardless of molecular subtype; and breast cancer patients' preferences for adjuvant radiation therapy post lumpectomy, whole-breast irradiation versus partial-breast irradiation: a single-institutional study. ## [4] The proceedings contain 12 papers. The topics discussed include: dexamethasone versus placebo in the prophylaxis of radiation-induced pain flare following palliative radiation therapy for bone metastases: a double-blind randomized, controlled, superiority trial; hypofractionated versus conventionally fractionated radiation therapy for prostate cancer: five-year oncologic outcomes of the Dutch randomized phase 3 HYPRO trial; patient-reported outcomes in NRG oncology/RTOG 0938, a randomized phase 2 study evaluating 2 ultrahypofractionated regimens (UHRs) for prostate cancer; report of NRG oncology/RTOG 9601, a phase 3 trial in prostate cancer: anti-androgen therapy (AAT) with bicalutamide during and after radiation therapy (RT) in patients following radical prostatectomy (RP) with pT2-3pN0 disease and an elevated PSA; NRG oncology RTOG 0415: a randomized phase 3 noninferiority study comparing 2 fractionation schedules in patients with low-risk prostate cancer; accelerated partial breast irradiation using sole interstitial multicatheter brachytherapy versus whole breast irradiation for early breast cancer: five-year results of a randomized phase 3 trial - part I: local control and survival results; preclinical advances in combined-modality cancer immunotherapy with radiation therapy; and examination of industry payments to radiation oncologists in 2014
Add Comment